[HTML][HTML] Mechanisms of resistance to EGFR-targeted drugs: lung cancer
F Morgillo, CM Della Corte, M Fasano, F Ciardiello - ESMO open, 2016 - Elsevier
Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …
[HTML][HTML] Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive …
F Wang, XY Diao, X Zhang, Q Shao, YF Feng… - Cancer …, 2019 - Springer
Background Identification of activated epidermal growth factor receptor (EGFR) mutations
and application of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have greatly changed the …
and application of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have greatly changed the …
Targeting epidermal growth factor receptor: central signaling kinase in lung cancer
T Yoshida, G Zhang, EB Haura - Biochemical pharmacology, 2010 - Elsevier
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide.
Platinum-based doublets remain the current standard therapy for advanced NSCLC …
Platinum-based doublets remain the current standard therapy for advanced NSCLC …
[HTML][HTML] Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Background Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
[HTML][HTML] A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
A Russo, T Franchina, GRR Ricciardi, A Picone… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small
Cell Lung Cancer (NSCLC) launched the era of personalized medicine in advanced …
Cell Lung Cancer (NSCLC) launched the era of personalized medicine in advanced …
[HTML][HTML] Hype or hope–Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant …
F Papini, J Sundaresan, A Leonetti, M Tiseo… - Critical Reviews in …, 2021 - Elsevier
Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …
[HTML][HTML] Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
K Kobayashi, K Hagiwara - Targeted oncology, 2013 - Springer
Before 2009, nonsmall cell lung cancer (NSCLC) was one disease entity treated by cytotoxic
chemotherapy that provided a response rate of 20–35% and a median survival time (MST) of …
chemotherapy that provided a response rate of 20–35% and a median survival time (MST) of …
Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and …
E Massarelli, FM Johnson, HS Erickson, II Wistuba… - Lung Cancer, 2013 - Elsevier
Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …
[HTML][HTML] Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
R Rosell, AF Cardona, O Arrieta, A Aguilar… - British Journal of …, 2021 - nature.com
Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …
EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now?
YL Wu - Trends in Pharmacological Sciences, 2016 - cell.com
Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …